Insider Purchases: Inside the Buy
Tag: CFO Bought Shares
Fiserv: Can Its Clover Come with Four Leaves Or Is It Just Three for Faith, Hope, and Love?
Insiders are buying, institutions are loading up, shorts are barely awake, and Fiserv now trades at deep-value multiples. With Clover, cash flow, and a credible turnaround plan, is this three-leaf fintech about to sprout a fourth? 🍀
Insiders Buy Shares Again; Can Energizer Regain Power?
Energizer insiders keep loading up on shares while institutions hold more than the float. Meanwhile, guidance dips and tariffs bite. Is ENR a contrarian deep-value gem ready to recharge — or a battery running low? Here’s the fun, funny breakdown. 🔋🐰
Insiders Purchase Shares of Goosehead Insurance — Should You Buy, Duck, or Just Take a Gander?
Insiders are loading up on Goosehead Insurance shares — and institutions can’t get enough. With strong growth but real risks, is this goose ready to fly… or cooked? Here’s the fun, smart breakdown. 🪿📈🔥
Freshworks Insider Buys: Are FRSH Shares Finally Getting… Fresh?
Freshworks insiders just went shopping — and not for office snacks. The CEO/President and CFO/COO bought shares, hinting that FRSH may finally be ready to rise. Here’s the fun, funny breakdown of why insiders love it… and whether you should too.
Insiders Just Boarded: Will NCLH’s Next Port Be Higher Prices?
Three top insiders at Norwegian Cruise Line (NCLH) bought shares on the same day—while bookings hit records and revenue sails higher. Debt is still the big wave to watch, but valuation looks reasonable for a cyclical. Here’s what cluster buys, guidance, and leverage really mean for the stock.
Absci: When AI Meets Antibodies — and Insiders Can’t Resist Buying More!
AI is designing drugs, and Absci is leading the charge — with insider confidence, top-tier partners, and a cash runway through 2028. Still pre-revenue but packed with promise, this biotech might just be the next NVIDIA of antibodies.
Insiders Think Marvell Is a Wonder at Current Price; Should You Emulate the CEO, CFO, and Presidents and Buy MRVL?
Insiders, buybacks, and AI growth — oh my! Marvell Technology’s execs just bought millions in stock. With a $5B buyback, should you marvel too?
Novocure (NVCR): From Electric Fields to Fighting Cancer — and Maybe Lifting Portfolios?
Novocure is zapping cancer cells with Tumor Treating Fields — and maybe giving investors a shock of opportunity. With insiders and institutions piling in, can NVCR rebound 94% from its crash? ⚡📈
Coty Class A (COTY): When Perfume Meets Portfolio
Coty’s stock is trading like discount lipstick, but insiders — including the CEO — are buying big. Is this a makeover moment or another smudge?
MaxCyte (MXCT) — Insiders Load Up While Cash Burns
MaxCyte insiders are shopping biotech shares like it’s Black Friday 🛒💉. With revenue slipping, cash burning, but institutions holding, is MXCT a comeback spark ⚡ or a treadmill burn-out 🔥?